Yang Wei, Si Si-Cong, Wang Wei-Hua, Li Jing, Ma Yi-Xin, Zhao Huan, Liu Jia
Department of Geriatrics, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.
Front Microbiol. 2025 Jan 28;16:1526764. doi: 10.3389/fmicb.2025.1526764. eCollection 2025.
Primary sarcopenia is characterized by a progressive loss of skeletal muscle mass, strength, and physical function that occurs with aging. Despite the related adverse or even serious health outcomes, no medications are currently available for treating primary sarcopenia. Here, we discuss recent advancements in understanding the mechanistic role of gut microbiota-muscle cross-talk in primary sarcopenia, and the therapeutic implications. The mechanistic insights encompass a causal role of gut dysbiosis in primary sarcopenia, potentially mediated through gut microbiota-derived bioactive metabolites, such as short-chain fatty acids (SCFAs), secondary bile acids, and their associated signaling pathways, which may be translated into the development of new microbiome-based treatment and diagnostic approaches. Furthermore, we identify challenges that need addressing in future studies to facilitate the translation into potential novel treatment and differential diagnosis for older individuals with sarcopenia.
原发性肌肉减少症的特征是随着年龄增长，骨骼肌质量、力量和身体功能逐渐丧失。尽管会产生相关的不良甚至严重健康后果，但目前尚无药物可用于治疗原发性肌肉减少症。在此，我们讨论了在理解肠道微生物群与肌肉相互作用在原发性肌肉减少症中的机制作用方面的最新进展及其治疗意义。机制性见解包括肠道菌群失调在原发性肌肉减少症中的因果作用，这可能是通过肠道微生物群衍生的生物活性代谢产物介导的，如短链脂肪酸（SCFAs）、次级胆汁酸及其相关信号通路，这可能会转化为基于微生物群的新治疗和诊断方法的开发。此外，我们确定了未来研究中需要解决的挑战，以便为患有肌肉减少症的老年人转化为潜在的新治疗方法和鉴别诊断。
